



**RECEIVED
CENTRAL FAX CENTER**

APR 24 2006

Suite 2800 1100 Peachtree St.
Atlanta GA 30309-4530
t 404 815 6500 f 404 815 6555
www.KilpatrickStockton.com

April 24, 2006

direct dial 404 745 2463
direct fax 404 541 3269
SKulkarni@KilpatrickStockton.com

FAX

RECIPIENT/ PHONE NO.	FAX NO.	COMPANY/ CITY, STATE, COUNTRY
Examiner C.H. Yaen Group 1643 571-272-0838	571-273-8300	U.S. Patent and Trademark Office Alexandria, VA

Sima S. Kulkarni
FROM

7
PAGES (WITH COVER)

0982
REFERENCE NO

43170/296614
CLIENT/MATTER NO.

PLEASE CALL 404 815 6497 IF YOU HAVE DIFFICULTY WITH THIS TRANSMISSION.

CONFIDENTIALITY NOTE:

The information contained in this fax message is being transmitted to and is intended for the use of the individual named above. If the reader of this message is not the intended recipient, you are hereby advised that any dissemination, distribution or copy of this fax is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and destroy this fax message.

COMMENTS

In re Application of: Holaday et al.

Serial No. 10/799,163

Filed: March 12, 2004

Title: Compositions and Methods for Treating Cancer and Hyperproliferative Disorders

Papers Enclosed:

Amendment Transmittal

Amendment and Response to Restriction Requirement

TO BE COMPLETED BY KS OPERATIONS CENTER

TRANSMISSION RECEIPT DATE/TIME: _____

COMPLETED BY: _____

JOB CODE

51502

ATLANTA AUGUSTA CHARLOTTE LONDON NEW YORK RALEIGH STOCKHOLM WASHINGTON WINSTON-SALEM

PATENTS

IN THE U.S. PATENT AND TRADEMARK OFFICE

In re Application of:

Docket No. 05213-0077 (43170-296614)

HOLADAY ET AL.

Serial No. 10/799,163

Filed: March 12, 2004

For: COMPOSITIONS AND METHODS FOR TREATING CANCER AND HYPERPROLIFERATIVE DISORDERS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RECEIVED
CENTRAL FAX CENTER

APR 24 2006

Sir:

Transmitted herewith is a paper in the above-identified application.

- ☒ Amendment and Response to Restriction Requirement.
☒ Applicant claims small entity status.
☒ No additional fee is required.
☐ The additional fee is calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST PREVIOUSLY PAID FOR	PRESENT EXTRA	SMALL ENTITY		OTHER THAN SMALL ENTITY	
					RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	11	MINUS	20=	0	x25	\$	x50	\$
INDEP.	2	MINUS	3 =	0	x100	\$	x200	\$
FIRST PRESENTATION OF								
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS					+180	\$	+360	\$
TOTAL					ADDITIONAL FEE		\$	
					\$0		\$	


- ☐ A check in the amount of \$ is attached.
☐ Form PTO-2038 is attached, authorizing the charge of \$.
☒ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16, or credit any overpayment, to Account No. 11-0855. A duplicate copy of this sheet is enclosed.

I hereby certify that this correspondence is being facsimile transmitted to the
 United States Patent and Trademark Office (Fax No. 571-273-8300) on
 April 24, 2006.



Sima Singadia Kulkarni - Reg. No. 43,732

KILPATRICK STOCKTON LLP
 1100 Peachtree Street
 Suite 2800
 Atlanta, Georgia 30309-4530
 Telephone: 404/815-6500



By: _____
 Sima Singadia Kulkarni, Attorney for Applicant
 Reg. No. 43,732

RECEIVED
CENTRAL FAX CENTER

APR 24 2006

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

HOLADAY ET AL.

Serial No. 10/799,163

Filed: March 12, 2004

For: COMPOSITIONS AND METHODS FOR
TREATING CANCER AND
HYPERPROLIFERATIVE DISORDERS

Art Unit: 1643

Examiner: C. H. Yaen

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

In response to the Office Action dated March 24, 2006, please amend the above-identified application as follows.

No additional fees are believed due, however, the Commissioner is hereby authorized to charge any additional filing fee and credit any refund to Deposit Account No. 11-0855.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 4 of this paper.

Conclusion begins on page 5 of this paper.

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office (Fax No. 571-273-8300) on April 24, 2006.



Sima Singadia Kulkarni - Reg. No. 43,732

9262362.1